Garry Menzel Joins GHO Capital as Operating Partner

Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR2 Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering

GlobeNewswireApr 23 19:45

Form 144 | Stoke Therapeutics(STOK.US) Insider Proposes to Sell 41.76 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Apr 17, $Stoke Therapeutics(STOK.US)$ Insider Ezbon International Limited intends to sell 3.6 million shares of its common stock on Apr 17, with a total market value of approxi

Futu NewsApr 18 04:22

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK

Stoke TherapeuticsApr 17 12:00

Buy Rating Justified by Stoke Therapeutics' Promising Pipeline and Strategic Market Positioning

TipRanksApr 11 18:27

Needham: Reiterates Stoke Therapeutics (STOK.US) rating and adjusted from buy to buy rating, target price is $22.00.

Needham: Reiterates Stoke Therapeutics (STOK.US) rating and adjusted from buy to buy rating, target price is $22.00.

Zhitong FinanceApr 11 18:20

Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target

Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.

BenzingaApr 11 18:14